These observations confirm what described for CLL patients and pave the way to test the impact of ADO-targeting therapies, alone or in combination with drugs that directly target the leukemic clone to magnify therapeutic responses. The gene discussed is ADO; the disease is B-cell chronic lymphocytic leukemia.